Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01505088 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis
A Phase 3 study, sponsored by Eyegate Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 193
- Enrollment target
NCT01505088 is a Phase 3 study that has completed, run by Eyegate Pharmaceuticals. The registered enrollment target is 193 participants.
The verdict
NCT01505088, a Phase 3 study, has completed, sponsored by Eyegate Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 193 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.
Interventions
- DRUG Placebo Eyedrops
- DRUG 40 mg/mL Dexamethasone phosphate ophthalmic solution
- DRUG Prednisolone Acetate (1%) Eyedrops
- DRUG 100 mM sodium citrate buffer solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01505088
The ClinicalTrials.gov registry entry for NCT01505088 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eyegate Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo Eyedrops is the first listed.
NCT01505088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01505088 about?
NCT01505088 is a clinical study titled "Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis". The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior seg...
What is the current status of trial NCT01505088?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 193 participants. The study started on 2011-12. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01505088?
The interventions under investigation include: Placebo Eyedrops (DRUG), 40 mg/mL Dexamethasone phosphate ophthalmic solution (DRUG), Prednisolone Acetate (1%) Eyedrops (DRUG), 100 mM sodium citrate buffer solution (DRUG).
Who is sponsoring clinical trial NCT01505088?
This trial is sponsored by Eyegate Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.